Academic Highlights: Clinical Insights Into Pharmacogenetics and Schizophrenia, Part 1 [CME]
J Clin Psychiatry 2008;69(3):487-494
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.
Schizophrenia is a heterogeneous
disorder in terms of
course and treatment response. The
field of pharmacogenetics, which
seeks to reveal how genetic factors
affect patients’ response to drugs,
holds promise to help clinicians develop
a better understanding of antipsychotic
such as which patients
might respond better or worse
to specific agents or treatment in
general or which patients might be at
particular risk for serious adverse
What do practicing psychiatrists
need to know about using